Skip to main content
Fig.Ā 4 | Clinical Sarcoma Research

Fig.Ā 4

From: A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis

Fig.Ā 4

Frequency of CDKN2A mutations per histologic sarcoma type in Foundation Medicine dataset (nā€‰=ā€‰7733). Copy number changes (orange) dominate the mutational landscape with infrequent occurrences of SNVs (green) and rearrangements (purple). The overall prevalence of CDKN2A mutations in sarcoma (left most bar) is 16.7% (nā€‰=ā€‰7733), with the highest mutated tumor being MPNST (60.7%, nā€‰=ā€‰262) followed by myxofibrosarcoma (29.3%, nā€‰=ā€‰140), and undifferentiated pleomorphic sarcoma (26.8%, nā€‰=ā€‰372)

Back to article page